Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

You’re reading our ESMO in 30 Seconds newsletter. Sign up here to get updates from the major European cancer conference in your inbox.

Hello again from Madrid, where we can tell you it’s Day 2 of the European Society for Medical Oncology’s annual meeting, but definitely not what day of the week it is. Perhaps some of the other nearly 40,000 people here can relate?

Enjoy today’s newsletter; we’ll be back with one more edition wrapping up the conference Monday afternoon. And on Thursday, join us for The STAT Recap, where we’ll catch you up on all the ESMO news you need to know, and answer your questions live. 

1. 

   Europe Correspondent

   Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.

2. 

   Senior Writer, Biotech

   Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.